| Literature DB >> 12815382 |
Abstract
The discovery and development of the bicyclam AMD3100--a chemokine receptor antagonist--has highlighted the therapeutic potential of such compounds in HIV infection, inflammatory diseases, cancer and stem-cell mobilization. Here, I describe the development process of AMD3100, which began about 15 years ago with the isolation of an impurity, and the basis for the clinical application of AMD3100 and its congeners.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12815382 DOI： 10.1038/nrd1134
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694